We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rena Yadlapati

Rena Yadlapati MD, MSHS

Associate Professor of Clinical Medicine and Medical Director, Esophageal Diseases & Motility, UCSD Center for Esophageal Diseases, Division of Gastroenterology, University of California San Diego, La Jolla, California

Dr. Yadlapati specializes in esophageal disorders, specifically GERD and esophageal dysmotility. Dr. Yadlapati is a co-author of national guidelines for achalasia and esophageal physiologic testing, the co-chair and first author of Chicago Classification version 4.0, and serves on the board of directors of the American College of Gastroenterology (ACG) Institute as well as the American Foregut Society. She is an active clinical researcher with grant support from the NIH and ACG, and has published over 90 articles in peer-reviewed publications.

Disclosures

Dr. Yadlapati reports the following:
  • Consultant: Medtronic (Institutional), Ironwood Pharmaceuticals (Institutional), Diversatek (Institutional), Phathom Pharmaceuticals
  • Medical Advisory Board with Stock Options: RJS Mediagnostix
  • Research Funding: Ironwood Pharmaceuticals

Recent Contributions to PracticeUpdate:

  1. Clinical Utility of Provocative Maneuvers in Esophageal High-Resolution Manometry
  2. Esophagogastric Junction Distensibility Predicts Treatment Response in Achalasia
  3. Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With GERD
  4. Most Patients With GERD Who Failed PPI Therapy Also Have Functional Esophageal Disorders
  5. The Cytosponge Is Accurate and Safe for Assessing Histologic Activity in Eosinophilic Esophagitis